MSC Exosomes for Eye & Retinal Conditions
Mesenchymal stem cell (MSC)-derived exosomes are studied in regenerative research for the eye and retina. This overview is provided for research and educational purposes only.
What MSC exosomes are
MSC-derived exosomes are nanoscale, cell-free extracellular vesicles (roughly 30–150 nm) that carry signaling cargo such as proteins, lipids, and microRNA. They are not stem cells, and BioRegenEx supplies them as characterized, research-use-only material with per-lot documentation.
What the research explores
In preclinical ophthalmology research, MSC-derived exosomes and secretome have been studied for signaling related to retinal ganglion cell protection, diabetic retinopathy, glaucoma, dry eye, and retinopathy of prematurity. These are research findings only and do not establish a clinical treatment. The studies are indexed in our Exosome Research Library under Eye & Retina.
Why sourcing and characterization matter
Because exosome composition depends on the source cells and manufacturing, research-grade material is defined by measurement — particle size and concentration, sterility and endotoxin screening, and a per-lot Certificate of Analysis.
Frequently Asked Questions
Are MSC exosomes an approved eye treatment?
No. MSC-derived exosomes are not FDA-approved to treat any eye condition and are supplied for research use only (RUO).
What does the eye research focus on?
Preclinical research focuses on neuroprotective and anti-inflammatory signaling in retinal and ocular surface models.
Key Published Research
Human clinical evidence listed first, then preclinical. Every entry links to its PubMed record.
- Efficacy of topical mesenchymal stem cell exosome in Sjogren syndrome-related dry eye: a randomized clinical trial. BMC Ophthalmol, 2025. HUMAN randomized controlled trial (Phase I/II). (PubMed)
- Mesenchymal stem cell-sourced exosomes as potentially novel remedies for severe dry eye disease. J Ophthalmol, 2025. Review. (PubMed)
- Mesenchymal stem cell-derived exosomes for ocular diseases: therapeutic mechanisms and clinical perspectives. Int J Nanomedicine, 2025. Review. (PubMed)
- miR-204-containing exosomes ameliorate GVHD-associated dry eye disease. Sci Adv, 2022. Preclinical. (PubMed)
- Exosome-loaded thermosensitive hydrogels for corneal epithelium and stroma regeneration. Biomaterials, 2022. Preclinical. (PubMed)
- Mesenchymal stem cell-derived extracellular vesicles and retinal ischemia-reperfusion injury. Biomaterials, 2019. Preclinical. (PubMed)
For research and educational purposes; research-use-only.
These statements have not been evaluated by the FDA. BioRegenEx supplies MSC-derived exosomes for research use only (RUO); they are not intended to diagnose, treat, cure, or prevent any disease. This content is educational and is not medical advice.